The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
CRISPR-based detection enables highly specific molecular recognition
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Hemant Surgical Industries receives order
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The facility has been designed with a dual focus on efficiency and sustainability
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Subscribe To Our Newsletter & Stay Updated
